Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Metformin
100%
Glucagon-like
100%
Randomized Crossover Trial
100%
Postprandial Effect
100%
Glucose-lowering Drugs
57%
Metformin Treatment
57%
Postprandial Glucose
42%
Exendin (9-39)
42%
Fasting Plasma Glucose
28%
Saline Injection
28%
Glucagon-like peptide-1 Receptor (GLP-1R)
28%
Antagonization
28%
Body Mass Index
14%
Treatment Duration
14%
Placebo
14%
Randomized Placebo-controlled Trial
14%
A1 Receptor
14%
AIMS™
14%
Receptor Antagonist
14%
Beneficial Effects
14%
Hemoglobin A1c (HbA1c)
14%
Trial Registration
14%
Mediating Effect
14%
Placebo Treatment
14%
Type 2 Diabetes Prevention
14%
Glucose Tolerance
14%
Meal Tolerance Test
14%
Glucose Excursion
14%
Response Mean
14%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Glycon
100%
Glucagon Like Peptide 1
100%
Placebo
30%
Infusion
30%
Glucagon Like Peptide 1 Receptor
30%
Exendin 9
30%
Receptor Antagonist
10%
Body Mass Index
10%
Hemoglobin A1c
10%
Medicine
10%
Glucose Tolerance
10%
Test Meal
10%
Pharmacology, Toxicology and Pharmaceutical Science
Metformin
100%
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon-Like Peptide-1
100%
Placebo
30%
Glucagon-Like Peptide 1 Receptor
30%
Exendin 9
30%
Receptor Antagonist
10%
Hemoglobin A1c
10%
Biochemistry, Genetics and Molecular Biology
Glucagon-Like Peptide-1
100%
Glucose Blood Level
50%
Glucagon-Like Peptide 1 Receptor
50%
Glucagon Blood Level
33%
Body Mass
16%
Receptor Antagonist
16%
Agricultural and Biological Sciences
Glucagon-Like Peptide-1
100%
Placebo
37%
Receptor
25%
Eicosanoid Receptor
25%
Body Mass Index
12%
Glucose Tolerance
12%
Test Meal
12%
Cross-over Studies
12%
Glucagon-Like Peptide 1 Receptor
12%